Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Outlook on the World’s Anti-venom Market, 2019-2024 - Polyvalent Antivenoms Poised to Register Robust Growth - ResearchAndMarkets.com

November 21, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 21, 2019--

The “Anti-venom Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.

The anti-venom market is expected to register a CAGR of nearly 4.7% during the forecast period, 2019-2024.

  • Snakebite is a neglected public health issue in many tropical and subtropical countries. About 5 million snake bites occur each year, resulting in up to 2.5 million envenomings (poisoning from snake bites) and at least 100,000 deaths, and around three times as many amputations and other permanent disabilities.
  • Due to the involvement of international health organizations in producing safe and effective anti-venoms, people are aware of the anti-venom drugs.
  • Anti-venom production is difficult and expensive. The cost of several anti-venoms has increased dramatically over the last two decades, making treatment unaffordable for most of the people who are in need of it.
  • Inappropriate procurement and medicine distribution strategies in few countries contribute to manufacturers ceasing the production of anti-venom or increasing the prices of anti-venom.

Key Market Trends

Polyvalent Antivenoms Segment Poised to Register Robust Growth

Polyvalent antivenoms comprise particular antibodies that are capable of counteracting a number of homologous venoms from various species/genera. Polyvalent antivenoms can save lives of victims of snake envenomation, even when the culprit snake is unknown, most usual case, about 80% of all the time, and when a monovalent antivenom can not be chosen. They are beneficial in regions where there is a presence of large number of venomous species and when it is difficult to produce monovalent antivenoms against all of them.

It is now possible to formulate polyvalent antivenoms with high potencies analogous to those of the equivalent monovalent antivenoms. With good manufacturing processes, these antivenoms have been shown to cause few and minor adverse reactions. Moreover, polyvalent antivenoms demonstrated a wide range of Para specific neutralization of poisons from different species/genera, even from distant geographic areas. Lastly, it is less expensive and easier to produce and handle.

The United States is Expected to Retain the Largest Market Share During the Forecast Period

Geographically, North America holds the largest market share with respect to demand and revenue. In the United States, every state, except Maine, Alaska, and Hawaii, is home to at least one of the 20 venomous snake species. Up to 95% of all snakebite-related deaths in the United States are attributed to the western and eastern diamondback rattlesnakes.

Furthermore, the majority of bites in the United States occur in the south-western part of the country, as the rattlesnake population in the eastern states are much lower. The United States contributes a major share to the anti-venom market, due to the establishment of snake poison control centers, increase in antivenom products, and rise in clinical trial conducting firms for anti-venom products, and established healthcare facilities in the region.

Competitive Landscape

Several developing countries with established biotechnological facilities have local scientific expertise, which creates favorable conditions to establish local antivenom manufacturing practices. Countries, such as Brazil, Costa Rica, Egypt, France, India, Mexico, South Africa, and Thailand, have large, well-established anti-venom manufacturers. Many companies from Costa Rica to Spain to India are developing new techniques to produce economically and medically promising African polyvalent anti-venoms.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Awareness on Antivenoms Available

4.2.2 Technological Advancements

4.3 Market Restraints

4.3.1 Complexities Involved in the Preparation of the Correct Immunogens

4.3.2 Lack of Regulatory Capacity for the Control of Antivenoms in Countries

4.4 Porter’s Five Force Analysis


5.1 By Species

5.1.1 Snake

5.1.2 Scorpion

5.1.3 Spiders

5.1.4 Other Species

5.2 By Antivenom Type

5.2.1 Polyvalent Antivenoms

5.2.2 Monovalent Antivenoms

5.2.3 Others

5.3 Geography

5.3.1 North America

5.3.2 Europe

5.3.3 Asia-Pacific

5.3.4 Middle East & Africa

5.3.5 South America


6.1 Company Profiles

6.1.1 Pfizer Inc.

6.1.2 Laboratorios Silanes (Bioclon Institute)

6.1.3 CSL Limited

6.1.4 BTG PLC

6.1.5 Merck & Co.

6.1.6 Merck KGaA (Sigma Aldrich)

6.1.7 Flynn Pharma (Micropharm)

6.1.8 Boehringer Ingelheim


For more information about this report visit https://www.researchandmarkets.com/r/7w1lvm

View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005634/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/21/2019 10:02 AM/DISC: 11/21/2019 10:02 AM